サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1427050

初代肝細胞の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 製品別、種別、用途またはアッセイ別、エンドユーザー別、地域別

Primary Hepatocytes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 316 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
初代肝細胞の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 製品別、種別、用途またはアッセイ別、エンドユーザー別、地域別
出版日: 2024年01月31日
発行: Fairfield Market Research
ページ情報: 英文 316 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の初代肝細胞の市場規模は、今後10年間の年間推定成長率（CAGR）は8.0%になるとみられ、2031年までに4億1,000万米ドルに達すると予測されるなど、大きな成長が見込まれています。この有望な軌道は、薬剤開発、検査、新しいがん治療法の開発における肝細胞の重要な役割によって、肝細胞の需要が増加していることを反映しています。

潜在的な医薬品候補の分析に肝細胞が日常的に採用されることで、新薬の開発が加速し、臨床試験への参入が早まります。検査モデルの信頼性は新薬開発の成否に大きく影響し、このプロセスにおける肝細胞の役割は極めて重要です。

技術の進歩により、動物モデルへの依存度は徐々に低下しており、ますます生体内に近いシステムが好まれるようになっています。この動向は、当面の間、初代肝細胞の需要を牽引すると予想されます。

がんの有病率の上昇とがん治療に対する需要の高まりが、初代肝細胞を含む研究に拍車をかけています。個々の患者の特性に基づいてオーダーメイドの治療法を提供する個別化医療は、個別化薬の開発のために初代肝細胞に依存しています。その結果、初代肝細胞の市場は、個別化治療薬の需要の高まりと並行して成長しています。

当レポートでは、世界の初代肝細胞市場について調査し、市場の概要とともに、製品別、種別、用途またはアッセイ別、エンドユーザー別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 生産高と貿易統計、2018年～2023年

第4章 価格分析、2018年～2023年

第5章 世界の初代肝細胞市場の見通し、2018年～2031年

  • 世界の初代肝細胞市場の見通し、製品別、金額（100万米ドル）、数量（100万個）、2018年～2031年
  • 世界の初代肝細胞市場の見通し、種別、金額（100万米ドル）、数量（100万個）、2018年～2031年
  • 世界の初代肝細胞市場の見通し、用途またはアッセイ別、金額（100万米ドル）、数量（100万個）、2018年～2031年
  • 世界の初代肝細胞市場の見通し、エンドユーザー別、金額（100万米ドル）、数量（100万個）、2018年～2031年
  • 世界の初代肝細胞市場の見通し、地域別、金額（100万米ドル）、数量（100万個）、2018年～2031年

第6章 北米の初代肝細胞市場の見通し、2018年～2031年

第7章 欧州の初代肝細胞市場の見通し、2018年～2031年

第8章 アジア太平洋の初代肝細胞市場の見通し、2018年～2031年

第9章 ラテンアメリカの初代肝細胞市場の見通し、2018年～2031年

第10章 中東・アフリカの初代肝細胞市場の見通し、2018年～2031年

第11章 競合情勢

  • 製品対用途またはアッセイのヒートマップ
  • 企業の市場シェア分析、2022年
  • 競合ダッシュボード
  • 企業プロファイル
    • Thermo Fisher Scientific
    • Corning Inc.
    • Lonza
    • Axol Bioscience Ltd.
    • LifeNet Health
    • SEKISUI XenoTech, LLC
    • Cytes Biotechnologies
    • Cell Biologics, Inc.
    • ZenBio, Inc.
    • BioIVT.
    • ScienCell Research Laboratories, Inc.
    • Kerafast

第12章 付録

目次

Unveiling Opportunities, Challenges, and Country-wise Insights

Global Market Overview:

The global primary hepatocytes market is poised for significant growth, projected to reach a value of US$ 410 Mn by 2031, with an estimated Compound Annual Growth Rate (CAGR) of 8.0% over the next decade. This promising trajectory reflects the increasing demand for primary hepatocytes, driven by their crucial role in drug development, testing, and the development of new cancer treatments.

Opportunities for Primary Hepatocyte Manufacturers:

The routine adoption of hepatocytes for analyzing potential medication candidates accelerates the development of novel medicines and expedites their entry into clinical trials. The reliability of testing models significantly influences the success of developing novel medication therapies, emphasizing the pivotal role of hepatocytes in this process.

Advancements in technology are progressively reducing the reliance on animal models, favoring increasingly in vivo-like systems. This trend is expected to drive the demand for primary hepatocytes in the foreseeable future.

The growing prevalence of cancer and the escalating demand for cancer therapy have spurred research involving primary hepatocytes. Personalized medicine, which offers tailored treatment options based on individual patient characteristics, relies on primary hepatocytes for the development of personalized medications. Consequently, the market for primary hepatocytes has witnessed parallel growth alongside the rise in demand for personalized therapeutics.

Liver transplantation remains the optimal treatment for hepatic illness caused by various factors such as viruses, oncogenes, medications, or surgical removal. However, the scarcity of suitable liver donors presents challenges in meeting medical demands. To address this issue, alternative options such as hepatocyte transplantation are being explored, driving immediate demand for primary hepatocytes and fostering market development.

Stringent regulations set by various regulatory bodies emphasize ensuring the well-being of animals used in experiments. These regulations, coupled with researchers' self-imposed limits, have led to an increased demand for in-vivo models, presenting opportunities for primary hepatocyte providers to meet these regulatory standards and cater to the growing market demand.

Challenges Impacting Demand:

Despite the promising growth outlook, challenges persist in maintaining the demand for primary hepatocytes. Availability of other cell types for drug screening, along with the high risk of contamination and the intricate maintenance requirements of hepatocytes, pose constraints on market expansion. Additionally, the limited lifespan of freshly-isolated hepatocytes and the susceptibility to contamination hinder their widespread adoption.

Country-wise Insights:

  • United States: With approximately 84.7% market share in the North American primary hepatocytes culture market, the U.S. presents a lucrative landscape fueled by increasing investments in R&D programs and strategic business expansions.
  • Germany: Holding the largest market share in Europe, Germany benefits from the presence of major industry players, fostering accessibility and steady growth in the primary hepatocytes market.
  • China: Emerging as a prominent market, China exhibits substantial growth potential driven by extensive research activities, collaborative initiatives, and significant R&D investments.
  • India: With a considerable share in the South Asia primary hepatocytes market, India showcases a growing adoption of modern medicines and newer therapies, supported by increasing affordability and acceptance of biological drugs.

Competitive Landscape: Leading providers such as Thermo Fisher Scientific, Corning Inc., Lonza, and others are strategically positioning themselves through alliances, product launches, patents, and acquisitions to capitalize on the burgeoning opportunities in the primary hepatocytes industry.

Key Companies Profiled in the market include:

  • Thermo Fisher Scientific
  • Corning Inc.
  • Lonza
  • Axol Bioscience Ltd.
  • LifeNet Health
  • SEKISUI XenoTech, LLC
  • Cytes Biotechnologies
  • Cell Biologics, Inc.
  • ZenBio, Inc.
  • BioIVT.
  • ScienCell Research Laboratories, Inc.
  • Kerafast
  • Takara Bio Inc.
  • Kosheeka

Key Segments Covered in Primary Hepatocytes Industry Survey

Primary Hepatocytes Market by Product:

  • Cryopreserved Suspension Hepatocytes
  • Fresh Suspension Hepatocytes
  • 3D (Spheroid) Hepatocytes
  • Expanded Hepatocytes (Plateable)
  • Non-characterized Hepatocytes

Primary Hepatocytes Market by Species:

  • Humans
  • Rats
  • Mice
  • Dogs
  • Monkeys
  • Horses
  • Others

Primary Hepatocytes Market by Application or Assay:

  • Cell Viability Assays
  • Cytochrome Enzyme Activity
  • High Content Cytotoxicity
  • Transporter Inhibition Assays
  • In Vitro Intrinsic Clearance
  • Phospholipoids Assays
  • Others

Primary Hepatocytes Market by End User:

  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organizations

Primary Hepatocytes Market by Region:

  • North America Primary Hepatocytes Market
  • Latin America Primary Hepatocytes Market
  • Europe Primary Hepatocytes Market
  • South Asia Primary Hepatocytes Market
  • East Asia Primary Hepatocytes Market
  • Oceania Primary Hepatocytes Market
  • The Middle East & Africa Primary Hepatocytes Market

Table of Contents

1. Executive Summary

  • 1.1. Global Primary Hepatocytes Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Production Output and Trade Statistics, 2018 - 2023

  • 3.1. Global Primary Hepatocytes Market Production Output, by Region, Value (US$ Mn) and Volume (Million Units), 2018 - 2023
    • 3.1.1. North America
    • 3.1.2. Europe x`
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. Middle East and Africa

4. Price Analysis, 2018 - 2023

  • 4.1. Global Average Price Analysis, by Product/ Species/ Application or Assay/ End User, US$ Per Unit, 2018 - 2023
  • 4.2. Prominent Factor Affecting Primary Hepatocytes Prices
  • 4.3. Global Average Price Analysis, by Region, US$ Per Unit

5. Global Primary Hepatocytes Market Outlook, 2018 - 2031

  • 5.1. Global Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Cryopreserved Suspension Hepatocytes
      • 5.1.1.2. Fresh Suspension Hepatocytes
      • 5.1.1.3. 3D (Spheroid) Hepatocytes
      • 5.1.1.4. Expanded Hepatocytes (Plateable)
      • 5.1.1.5. Non-characterized Hepatocytes
  • 5.2. Global Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Humans
      • 5.2.1.2. Rats
      • 5.2.1.3. Mice
      • 5.2.1.4. Dogs
      • 5.2.1.5. Monkeys
      • 5.2.1.6. Horses
      • 5.2.1.7. Others
  • 5.3. Global Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Cell Viability Assays
      • 5.3.1.2. Cytochrome Enzyme Activity
      • 5.3.1.3. High Content Cytotoxicity
      • 5.3.1.4. Transporter Inhibition Assays
      • 5.3.1.5. In Vitro Intrinsic Clearance
      • 5.3.1.6. Phospholipoids Assays
      • 5.3.1.7. Others
  • 5.4. Global Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Biopharmaceutical Companies
      • 5.4.1.2. Academic and Research Institutes
      • 5.4.1.3. Contract Research Organizations
  • 5.5. Global Primary Hepatocytes Market Outlook, by Region, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. North America
      • 5.5.1.2. Europe
      • 5.5.1.3. Asia Pacific
      • 5.5.1.4. Latin America
      • 5.5.1.5. Middle East & Africa

6. North America Primary Hepatocytes Market Outlook, 2018 - 2031

  • 6.1. North America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Cryopreserved Suspension Hepatocytes
      • 6.1.1.2. Fresh Suspension Hepatocytes
      • 6.1.1.3. 3D (Spheroid) Hepatocytes
      • 6.1.1.4. Expanded Hepatocytes (Plateable)
      • 6.1.1.5. Non-characterized Hepatocytes
  • 6.2. North America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Humans
      • 6.2.1.2. Rats
      • 6.2.1.3. Mice
      • 6.2.1.4. Dogs
      • 6.2.1.5. Monkeys
      • 6.2.1.6. Horses
      • 6.2.1.7. Others
  • 6.3. North America Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Cell Viability Assays
      • 6.3.1.2. Cytochrome Enzyme Activity
      • 6.3.1.3. High Content Cytotoxicity
      • 6.3.1.4. Transporter Inhibition Assays
      • 6.3.1.5. In Vitro Intrinsic Clearance
      • 6.3.1.6. Phospholipoids Assays
      • 6.3.1.7. Others
  • 6.4. North America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Biopharmaceutical Companies
      • 6.4.1.2. Academic and Research Institutes
      • 6.4.1.3. Contract Research Organizations
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. North America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. U.S. Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.2. U.S. Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.3. U.S. Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.4. U.S. Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.5. Canada Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.6. Canada Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.7. Canada Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 6.5.1.8. Canada Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Europe Primary Hepatocytes Market Outlook, 2018 - 2031

  • 7.1. Europe Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Cryopreserved Suspension Hepatocytes
      • 7.1.1.2. Fresh Suspension Hepatocytes
      • 7.1.1.3. 3D (Spheroid) Hepatocytes
      • 7.1.1.4. Expanded Hepatocytes (Plateable)
      • 7.1.1.5. Non-characterized Hepatocytes
  • 7.2. Europe Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Humans
      • 7.2.1.2. Rats
      • 7.2.1.3. Mice
      • 7.2.1.4. Dogs
      • 7.2.1.5. Monkeys
      • 7.2.1.6. Horses
      • 7.2.1.7. Others
  • 7.3. Europe Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Cell Viability Assays
      • 7.3.1.2. Cytochrome Enzyme Activity
      • 7.3.1.3. High Content Cytotoxicity
      • 7.3.1.4. Transporter Inhibition Assays
      • 7.3.1.5. In Vitro Intrinsic Clearance
      • 7.3.1.6. Phospholipoids Assays
      • 7.3.1.7. Others
  • 7.4. Europe Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Biopharmaceutical Companies
      • 7.4.1.2. Academic and Research Institutes
      • 7.4.1.3. Contract Research Organizations
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Europe Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Germany Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.2. Germany Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.3. Germany Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.4. Germany Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.5. U.K. Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.6. U.K. Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.7. U.K. Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.8. U.K. Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.9. France Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.10. France Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.11. France Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.12. France Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.13. Italy Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.14. Italy Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.15. Italy Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.16. Italy Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.17. Turkey Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.18. Turkey Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.19. Turkey Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.20. Turkey Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.21. Russia Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.22. Russia Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.23. Russia Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.24. Russia Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.25. Rest of Europe Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.26. Rest of Europe Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.27. Rest of Europe Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 7.5.1.28. Rest of Europe Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific Primary Hepatocytes Market Outlook, 2018 - 2031

  • 8.1. Asia Pacific Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Cryopreserved Suspension Hepatocytes
      • 8.1.1.2. Fresh Suspension Hepatocytes
      • 8.1.1.3. 3D (Spheroid) Hepatocytes
      • 8.1.1.4. Expanded Hepatocytes (Plateable)
      • 8.1.1.5. Non-characterized Hepatocytes
  • 8.2. Asia Pacific Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Humans
      • 8.2.1.2. Rats
      • 8.2.1.3. Mice
      • 8.2.1.4. Dogs
      • 8.2.1.5. Monkeys
      • 8.2.1.6. Horses
      • 8.2.1.7. Others
  • 8.3. Asia Pacific Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Cell Viability Assays
      • 8.3.1.2. Cytochrome Enzyme Activity
      • 8.3.1.3. High Content Cytotoxicity
      • 8.3.1.4. Transporter Inhibition Assays
      • 8.3.1.5. In Vitro Intrinsic Clearance
      • 8.3.1.6. Phospholipoids Assays
      • 8.3.1.7. Others
  • 8.4. Asia Pacific Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Biopharmaceutical Companies
      • 8.4.1.2. Academic and Research Institutes
      • 8.4.1.3. Contract Research Organizations
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Asia Pacific Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. China Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.2. China Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.3. China Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.4. China Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.5. Japan Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.6. Japan Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.7. Japan Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.8. Japan Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.9. South Korea Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.10. South Korea Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.11. South Korea Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.12. South Korea Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.13. India Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.14. India Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.15. India Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.16. India Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.17. Southeast Asia Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.18. Southeast Asia Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.19. Southeast Asia Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.20. Southeast Asia Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.21. Rest of Asia Pacific Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.22. Rest of Asia Pacific Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.23. Rest of Asia Pacific Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 8.5.1.24. Rest of Asia Pacific Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America Primary Hepatocytes Market Outlook, 2018 - 2031

  • 9.1. Latin America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 9.1.1. Key Highlights
      • 9.1.1.1. Cryopreserved Suspension Hepatocytes
      • 9.1.1.2. Fresh Suspension Hepatocytes
      • 9.1.1.3. 3D (Spheroid) Hepatocytes
      • 9.1.1.4. Expanded Hepatocytes (Plateable)
      • 9.1.1.5. Non-characterized Hepatocytes
  • 9.2. Latin America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 9.2.1. Key Highlights
      • 9.2.1.1. Humans
      • 9.2.1.2. Rats
      • 9.2.1.3. Mice
      • 9.2.1.4. Dogs
      • 9.2.1.5. Monkeys
      • 9.2.1.6. Horses
      • 9.2.1.7. Others
  • 9.3. Latin America Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 9.3.1. Key Highlights
      • 9.3.1.1. Cell Viability Assays
      • 9.3.1.2. Cytochrome Enzyme Activity
      • 9.3.1.3. High Content Cytotoxicity
      • 9.3.1.4. Transporter Inhibition Assays
      • 9.3.1.5. In Vitro Intrinsic Clearance
      • 9.3.1.6. Phospholipoids Assays
      • 9.3.1.7. Others
  • 9.4. Latin America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 9.4.1. Key Highlights
      • 9.4.1.1. Biopharmaceutical Companies
      • 9.4.1.2. Academic and Research Institutes
      • 9.4.1.3. Contract Research Organizations
    • 9.4.2. BPS Analysis/Market Attractiveness Analysis
  • 9.5. Latin America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 9.5.1. Key Highlights
      • 9.5.1.1. Brazil Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.2. Brazil Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.3. Brazil Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.4. Brazil Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.5. Mexico Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.6. Mexico Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.7. Mexico Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.8. Mexico Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.9. Argentina Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.10. Argentina Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.11. Argentina Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.12. Argentina Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.13. Rest of Latin America Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.14. Rest of Latin America Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.15. Rest of Latin America Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 9.5.1.16. Rest of Latin America Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa Primary Hepatocytes Market Outlook, 2018 - 2031

  • 10.1. Middle East & Africa Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 10.1.1. Key Highlights
      • 10.1.1.1. Cryopreserved Suspension Hepatocytes
      • 10.1.1.2. Fresh Suspension Hepatocytes
      • 10.1.1.3. 3D (Spheroid) Hepatocytes
      • 10.1.1.4. Expanded Hepatocytes (Plateable)
      • 10.1.1.5. Non-characterized Hepatocytes
  • 10.2. Middle East & Africa Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 10.2.1. Key Highlights
      • 10.2.1.1. Humans
      • 10.2.1.2. Rats
      • 10.2.1.3. Mice
      • 10.2.1.4. Dogs
      • 10.2.1.5. Monkeys
      • 10.2.1.6. Horses
      • 10.2.1.7. Others
  • 10.3. Middle East & Africa Primary Hepatocytes Market Outlook, by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 10.3.1. Key Highlights
      • 10.3.1.1. Cell Viability Assays
      • 10.3.1.2. Cytochrome Enzyme Activity
      • 10.3.1.3. High Content Cytotoxicity
      • 10.3.1.4. Transporter Inhibition Assays
      • 10.3.1.5. In Vitro Intrinsic Clearance
      • 10.3.1.6. Phospholipoids Assays
      • 10.3.1.7. Others
  • 10.4. Middle East & Africa Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 10.4.1. Key Highlights
      • 10.4.1.1. Biopharmaceutical Companies
      • 10.4.1.2. Academic and Research Institutes
      • 10.4.1.3. Contract Research Organizations
    • 10.4.2. BPS Analysis/Market Attractiveness Analysis
  • 10.5. Middle East & Africa Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 10.5.1. Key Highlights
      • 10.5.1.1. GCC Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.2. GCC Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.3. GCC Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.4. GCC Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.5. South Africa Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.6. South Africa Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.7. South Africa Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.8. South Africa Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.9. Egypt Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.10. Egypt Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.11. Egypt Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.12. Egypt Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.13. Nigeria Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.14. Nigeria Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.15. Nigeria Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.16. Nigeria Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.17. Rest of Middle East & Africa Primary Hepatocytes Market by Product, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.18. Rest of Middle East & Africa Primary Hepatocytes Market by Species, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.19. Rest of Middle East & Africa Primary Hepatocytes Market by Application or Assay, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
      • 10.5.1.20. Rest of Middle East & Africa Primary Hepatocytes Market by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
    • 10.5.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

  • 11.1. Product vs Application or Assay Heatmap
  • 11.2. Company Market Share Analysis, 2022
  • 11.3. Competitive Dashboard
  • 11.4. Company Profiles
    • 11.4.1. Thermo Fisher Scientific
      • 11.4.1.1. Company Overview
      • 11.4.1.2. Product Portfolio
      • 11.4.1.3. Financial Overview
      • 11.4.1.4. Business Strategies and Development
    • 11.4.2. Corning Inc.
      • 11.4.2.1. Company Overview
      • 11.4.2.2. Product Portfolio
      • 11.4.2.3. Financial Overview
      • 11.4.2.4. Business Strategies and Development
    • 11.4.3. Lonza
      • 11.4.3.1. Company Overview
      • 11.4.3.2. Product Portfolio
      • 11.4.3.3. Financial Overview
      • 11.4.3.4. Business Strategies and Development
    • 11.4.4. Axol Bioscience Ltd.
      • 11.4.4.1. Company Overview
      • 11.4.4.2. Product Portfolio
      • 11.4.4.3. Financial Overview
      • 11.4.4.4. Business Strategies and Development
    • 11.4.5. LifeNet Health
      • 11.4.5.1. Company Overview
      • 11.4.5.2. Product Portfolio
      • 11.4.5.3. Financial Overview
      • 11.4.5.4. Business Strategies and Development
    • 11.4.6. SEKISUI XenoTech, LLC
      • 11.4.6.1. Company Overview
      • 11.4.6.2. Product Portfolio
      • 11.4.6.3. Financial Overview
      • 11.4.6.4. Business Strategies and Development
    • 11.4.7. Cytes Biotechnologies
      • 11.4.7.1. Company Overview
      • 11.4.7.2. Product Portfolio
      • 11.4.7.3. Financial Overview
      • 11.4.7.4. Business Strategies and Development
    • 11.4.8. Cell Biologics, Inc.
      • 11.4.8.1. Company Overview
      • 11.4.8.2. Product Portfolio
      • 11.4.8.3. Financial Overview
      • 11.4.8.4. Business Strategies and Development
    • 11.4.9. ZenBio, Inc.
      • 11.4.9.1. Company Overview
      • 11.4.9.2. Product Portfolio
      • 11.4.9.3. Financial Overview
      • 11.4.9.4. Business Strategies and Development
    • 11.4.10. BioIVT.
      • 11.4.10.1. Company Overview
      • 11.4.10.2. Product Portfolio
      • 11.4.10.3. Financial Overview
      • 11.4.10.4. Business Strategies and Development
    • 11.4.11. ScienCell Research Laboratories, Inc.
      • 11.4.11.1. Company Overview
      • 11.4.11.2. Product Portfolio
      • 11.4.11.3. Financial Overview
      • 11.4.11.4. Business Strategies and Development
    • 11.4.12. Kerafast
      • 11.4.12.1. Company Overview
      • 11.4.12.2. Product Portfolio
      • 11.4.12.3. Financial Overview
      • 11.4.12.4. Business Strategies and Development

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Report Assumptions
  • 12.3. Acronyms and Abbreviations